Pharmacy Grand Rounds
Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Is it O-K+? 

• ACPE Universal Activity Number (UAN): JA0000238-0000-20-028-L01-P
• Session Type: Knowledge-based
• CE Credits: A maximum of 0.75 contact hour (0.075 CEU) for the following: 
  • AAPA Category 1 CME Credits
  • ACPE
  • AMA PRA Category 1 Credits™
  • ANCC

• Session Fee: Free for Mayo Clinic staff

SESSION LOCATIONS

Live Session: (11:00am - 11:45am CST)

Until future notice, learners must watch Pharmacy Grand Rounds live via the web by going to the Video Exchange and selecting “Pharmacy Grand Rounds” in the “Streaming Now” section.

Participants may attend by viewing: Live Webcast
Video Recording - access two weeks after session date

COURSE DESCRIPTION

Cardiovascular disease is the leading cause of death in patients with end-stage renal disease (ESRD) on dialysis. In these patients, excessive amounts of aldosterone are associated with increased cardiovascular mortality. Use of mineralocorticoid receptor antagonists (MRAs) has been shown to reduce cardiovascular mortality in non-ESRD patients with heart failure with reduced ejection fraction and has been shown to be beneficial in treating resistant hypertension. However, there are concerns that using MRAs in the ESRD population increases the risk of hyperkalemia and hypotension. This presentation will review the safety and efficacy of MRAs in patients with ESRD.

At the conclusion of this knowledge-based CE session, participants should be able to:

• Discuss the role of MRAs in patients with ESRD
• Review the literature concerning risks and benefits of MRAs in patients with ESRD
• Outline a potential MRA treatment regimen for a patient with dialysis-dependent ESRD

Session Announcement

Session Slides

FACULTY INFORMATION

Hannah M. Brokmeier, PharmD
PGY1 Pharmacy Resident
Mayo Clinic Hospital - Rochester, MN

Hannah received a Doctor of Pharmacy degree from South Dakota State University in Brookings, SD.  She is a current PGY1 Pharmacy Resident at Mayo Clinic Hospital – Rochester with clinical practice interests in solid organ transplant and critical care.

DISCLOSURE STATEMENTS

As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program:

The faculty report the following relationships:

• Hannah M. Brokmeier, PharmD
  • Declares no financial relationships pertinent to this session
  • Declares off-label use of devices and medications will be discussed during this presentation, including:
    • Eplerenone
    • Spironolactone

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session.  Members include:

• Brenda Amaris
• Mary Ellen Cordes, MS, APRN, CNC, NE-BC
• Michael Huckabee, MPAS, PA-C, PhD
• Wayne (Nick) Nicholson, MD, PharmD, BCPS
• Garrett Schramm, PharmD, BCPS
• Lee Skrupky, PharmD, BCPS